Bioactivity | NF110 is a P2X3 receptor antagonist (Ki = 36 nM) and inactive toward P2Y receptors stably expressed (IC50s > 10 M). NF110 blocks alphabeta-methylene-ATP-induced currents (IC50 = 527 nM) in rat dorsal root ganglia neurons[1]. |
Target | Ki: 36 nM (P2X3 Receptor) |
Invitro | NF110 shows an activity in the human tumour cell line panel, with IC30 of 362.3 μM[2].NF110 inhibits HMGA2-DNA interactions with an IC50 of 0.87 μM[3]. |
In Vivo | NF110 shows potency at Endogenous P2X Receptors in Rat DRG Neurons, with a peak amplitude of 675 pA[1]. |
Name | NF110 |
CAS | 111150-22-2 |
Formula | C41H28N6Na4O17S4 |
Molar Mass | 1096.91 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Hausmann R, et al. The suramin analog 4,4',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol [2]. Dhar S, et al. Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients. Eur J Cancer. 2000;36(6):803-809. [3]. Su L, et al. Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays. Sci Rep. 2020;10(1):18850. Published 2020 Nov 2. |